Literature DB >> 22995296

Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.

Jiae Koh1, Saet-byul Lee, Hyunju Park, Hyo Jun Lee, Nam Hoon Cho, Jongsun Kim.   

Abstract

Natural killer cells are lymphocytes of the innate immune system that play a key role in the direct elimination of transformed or virus-infected cells. Recently, it has been reported that NK cells can attack cancer cells with stem cell-like properties. In this study, we isolated ovarian cancer cell lines CAOV3 and TOV21G with and without CD24, which has been reported as an ovarian cancer stem cell marker, and compared their drug resistance and susceptibility to NK cell lysis. The isolated CD24(+) CAOV3 and TOV21G cells were more resistant to cisplatin and doxorubicin anti-cancer drugs. Also, CD24(+) CAOV3 and TOV21G cells were more susceptible to NK cell lysis compared with CD24(-) cells. In order to identify reasons for the differing NK cell susceptibility, we examined NK cell-killing mechanisms against CD24(+) cancer cell lines by analyzing NKG2D ligands, MHC class I molecules, and natural cytotoxic receptor ligands expression on target cells. Consistently, CD24(+) CAOV3 and TOV21G cells showed up-regulated NKG2D ligands and down-regulated MHC class I molecule expression. These findings show that CD24(+) ovarian cancer cell lines are more resistant to antitumor drugs but are more susceptible to NK cell lysis; thus, NK cell immunotherapy might be useful in eliminating ovarian cancer stem cells and preventing tumor recurrence and metastasis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995296     DOI: 10.1016/j.bbrc.2012.09.067

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.

Authors:  Andrea Gras Navarro; Justyna Kmiecik; Lina Leiss; Mateusz Zelkowski; Agnete Engelsen; Øystein Bruserud; Jacques Zimmer; Per Øyvind Enger; Martha Chekenya
Journal:  J Immunol       Date:  2014-11-07       Impact factor: 5.422

2.  Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells.

Authors:  Yuta Kimura; Ryouichi Tsunedomi; Kiyoshi Yoshimura; Satoshi Matsukuma; Yoshitaro Shindo; Hiroto Matsui; Yukio Tokumitsu; Shin Yoshida; Michihisa Iida; Nobuaki Suzuki; Shigeru Takeda; Tatsuya Ioka; Shoichi Hazama; Hiroaki Nagano
Journal:  Ann Surg Oncol       Date:  2022-07-25       Impact factor: 4.339

Review 3.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

Review 4.  A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis.

Authors:  Antonino Bruno; Guido Ferlazzo; Adriana Albini; Douglas M Noonan
Journal:  J Natl Cancer Inst       Date:  2014-09-01       Impact factor: 13.506

5.  Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice.

Authors:  Janneke S Hoogstad-van Evert; Jeannette Cany; Dirk van den Brand; Manon Oudenampsen; Roland Brock; Ruurd Torensma; Ruud L Bekkers; Joop H Jansen; Leon F Massuger; Harry Dolstra
Journal:  Oncoimmunology       Date:  2017-05-11       Impact factor: 8.110

6.  Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.

Authors:  Ralph J Maas; Jolien van der Meer; Leon Massuger; Harry Dolstra; Janneke S Hoogstad-van Evert; Jeannette Cany; Sophieke van der Steen; Joop H Jansen; Jeffrey S Miller; Ruud Bekkers; Willemijn Hobo
Journal:  Oncotarget       Date:  2018-10-05

7.  Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.

Authors:  Rüdiger Klapdor; Shuo Wang; Michael Morgan; Thilo Dörk; Ulrich Hacker; Peter Hillemanns; Hildegard Büning; Axel Schambach
Journal:  Int J Mol Sci       Date:  2019-02-03       Impact factor: 5.923

Review 8.  The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers.

Authors:  Adrián Ramírez-de-Arellano; Julio César Villegas-Pineda; Christian David Hernández-Silva; Ana Laura Pereira-Suárez
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-21       Impact factor: 5.555

Review 9.  CD24: A Novel Target for Cancer Immunotherapy.

Authors:  Emmanouil Panagiotou; Nikolaos K Syrigos; Andriani Charpidou; Elias Kotteas; Ioannis A Vathiotis
Journal:  J Pers Med       Date:  2022-07-28

10.  Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.

Authors:  Veethika Pandey; Jeremiah L Oyer; Robert Y Igarashi; Sarah B Gitto; Alicja J Copik; Deborah A Altomare
Journal:  Oncotarget       Date:  2016-02-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.